Stock Analysis

How Much Are Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Insiders Spending On Buying Shares?

  •  Updated
NasdaqGM:ARCT
Source: Shutterstock

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), you may well want to know whether insiders have been buying or selling.

Do Insider Transactions Matter?

It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, such insiders must disclose their trading activities, and not trade on inside information.

We don't think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise'.

View our latest analysis for Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by CFO & Director Andrew Sassine for US$149k worth of shares, at about US$29.74 per share. Even though the purchase was made at a significantly lower price than the recent price (US$52.67), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Arcturus Therapeutics Holdings insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqGM:ARCT Insider Trading Volume February 28th 2021

Arcturus Therapeutics Holdings is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Arcturus Therapeutics Holdings Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Arcturus Therapeutics Holdings insiders own about US$137m worth of shares (which is 9.9% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Does This Data Suggest About Arcturus Therapeutics Holdings Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. It would be great to see more insider buying, but overall it seems like Arcturus Therapeutics Holdings insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 2 warning signs for Arcturus Therapeutics Holdings (1 is concerning!) that we believe deserve your full attention.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you decide to trade Arcturus Therapeutics Holdings, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted


What are the risks and opportunities for Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company.

View Full Analysis

Rewards

  • Earnings are forecast to grow 63.83% per year

Risks

No risks detected for ARCT from our risks checks.

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research on
Arcturus Therapeutics Holdings

ValuationFinancial HealthInsider TradingManagement Team